Skip to main content

Malik Fady Ibraham's Form 4 filing

Cytokinetics Inc (CYTK) · filed Jan 4, 2024

Accession no.
0001127602-24-000835
Filed
Jan 4, 2024
Trade date
Jan 4, 2024
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.36M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Malik Fady IbrahamCIK 0001551778Officer (EVP Research & Development)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 4, 2024Common StockMOption exerciseAcquired+11,678$7.96+$92,956.88162,651Direct
Jan 4, 2024Common StockSSaleDisposed−11,678$86.98−$1,015,752.44150,973Direct
Jan 4, 2024Common StockSSaleDisposed−4,000$86.99−$347,960146,973Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 4, 2024Common StockMOption exerciseDisposed−11,678$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)